AbCellera’s First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development

  AbCellera (Nasdaq: ABCL) announced today that Regeneron has elected to exercise its right to advance a therapeutic antibody candidate, discovered in partnership with AbCellera as part of a multi-target collaboration between the companies, into further preclinical development. The partnership, which commenced in March 2020 and allows for four discovery programs selected by Regeneron, leverages AbCellera’s antibody discovery engine and Regeneron’s VelocImmune® mice to identify novel therapeutic antibodies. This is the first potential candidate selected by Regeneron to move into further evaluation, and it targets an undisclosed G-protein coupled receptor (GPCR).

“By solving technology-intensive challenges that have hindered antibody discovery against difficult and sought-after drug targets, we’re able to open up opportunities for leading companies in our industry,” said Carl Hansen, Ph.D., CEO and President of AbCellera. “We are pleased our partnership with Regeneron has resulted in this first early-stage antibody candidate and look forward to continue empowering drug discovery for Regeneron’s clinical pipeline.”

Under the terms of the agreement, Regeneron has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbCellera receives research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties on net sales of products. AbCellera received a milestone payment for this antibody candidate and the amount of the payment was not disclosed.

https://www.biospace.com/article/releases/abcellera-s-first-program-with-regeneron-in-multi-target-collaboration-advances-in-preclinical-development/